VNRX vs. NGNE, CAPR, RNAC, OLMA, ADCT, NMRA, OCGN, HRTX, KOD, and CRVS
Should you be buying VolitionRx stock or one of its competitors? The main competitors of VolitionRx include Neurogene (NGNE), Capricor Therapeutics (CAPR), Cartesian Therapeutics (RNAC), Olema Pharmaceuticals (OLMA), ADC Therapeutics (ADCT), Neumora Therapeutics (NMRA), Ocugen (OCGN), Heron Therapeutics (HRTX), Kodiak Sciences (KOD), and Corvus Pharmaceuticals (CRVS). These companies are all part of the "pharmaceutical products" industry.
VolitionRx vs. Its Competitors
Neurogene (NASDAQ:NGNE) and VolitionRx (NYSE:VNRX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.
In the previous week, Neurogene had 1 more articles in the media than VolitionRx. MarketBeat recorded 2 mentions for Neurogene and 1 mentions for VolitionRx. Neurogene's average media sentiment score of 1.82 beat VolitionRx's score of 0.00 indicating that Neurogene is being referred to more favorably in the media.
VolitionRx has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than VolitionRx, indicating that it is currently the more affordable of the two stocks.
Neurogene has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Comparatively, VolitionRx has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.
52.4% of Neurogene shares are held by institutional investors. Comparatively, 8.1% of VolitionRx shares are held by institutional investors. 11.6% of Neurogene shares are held by insiders. Comparatively, 10.4% of VolitionRx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Neurogene has a net margin of 0.00% compared to VolitionRx's net margin of -2,321.14%. VolitionRx's return on equity of 0.00% beat Neurogene's return on equity.
Neurogene presently has a consensus target price of $46.17, suggesting a potential upside of 103.20%. VolitionRx has a consensus target price of $3.50, suggesting a potential upside of 366.67%. Given VolitionRx's stronger consensus rating and higher probable upside, analysts clearly believe VolitionRx is more favorable than Neurogene.
Summary
Neurogene beats VolitionRx on 9 of the 16 factors compared between the two stocks.
Get VolitionRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VNRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
VolitionRx Competitors List
Related Companies and Tools
This page (NYSE:VNRX) was last updated on 7/25/2025 by MarketBeat.com Staff
